Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Bioavailability of GX-I7 in Healthy Volunteers
NCT04283695Phase 1Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of efineptakin alfa in leukopenia (3 arms), sponsored by Seoul National University Hospital. Primary endpoint: Total radioactivity at feces, urine, blood to measure total recovery rate at 29 days. Status: unknown.
02
Drugs
efineptakin alfa
03
Conditions
leukopenia
Beyond the preview
Go deeper on NCT04283695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04283695.